HRS-4729 injection for adults with type 2 diabetes
Tests HRS-4729 injection in adults whose type 2 diabetes is not well controlled.
Plain-language title generated from the registry record
Registry title: A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
Key facts
- Where
- Tianjin and Wuhan, ChinaSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07843862, who can take part
Where in China
- Tianjin Medical University Chu Hsien-I Memorial HospitalTianjin, ChinaNo longer taking part
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & TechnologyWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Trial code
- NCT07843862
- Record updated
- 28 September 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.Read full original descriptionShow less
A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.
Inclusion: Have Type 2 Diabetes; Treated with diet and exercise alone or with a stable dose of metformin; Have an HbA1c value at screening of ≥7.5% and ≤10.5%.
Exclusion: History of any condition affecting gastric emptying, long-term use of medications directly affecting gastrointestinal motility, severe gastrointestinal disease, or prior gastrointestinal surgery; Have uncontrolled hypertension; Have Type 1 Diabetes, or specific types of diabetes; History of acute diabetic complications or severe hypoglycemic events; History of severe chronic diabetic complications, or non-proliferative diabetic retinopathy requiring treatment; History or known history of acute or chronic pancreatitis, or pancreatic injury; History or known history of acute cholecystitis, or symptomatic/treatment-requiring gallbladder disease; Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).